Posted by Michael Wonder on 09 Oct 2022
New federal incentives for diversity in clinical trials
8 October 2022 - In June 2022, the US House of Representatives passed legislation intended to increase the diversity of the populations enrolled in clinical trials of new drugs.
Under this bill, study sponsors would be required to submit a diversity action plan — including goals for study enrolment according to demographic group and steps for achieving those goals — for phase 3 or pivotal studies of new drugs.
